Biogen Re-Ups With Ionis In Search Of A Neuroscience 'Innovation Engine'
New 10-year collaboration, the sixth between the two firms, will attempt to bring seven antisense candidates for neurological indications to the clinic in the next two years. Biogen pays $1bn up front, split between cash and Ionis equity.
You may also be interested in...
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
EVP Michael Ehlers swaps public company scrutiny for early-stage, venture-funded opportunities at Apple Tree Partners and Limelight Bio, while CMO and longtime Biogen executive Alfred Sandrock reclaims R&D oversight role.
Still reeling from aducanumab’s failure in Phase III Alzheimer’s trial, Biogen management played up the company’s progress toward diversification and the promise of its pipeline.